BVS - Will a Powerful Acquisition Make This Early 2021 IPO a Buy?
Healthcare has become a hot topic of discussion over the past 18 months, including conversations about COVID-19 and its delta variant, debates over vaccination, and dialogues about the innovation and advancement in technologies to bring us more automation.
Bioventus (NASDAQ: BVS) is a company that specializes in developing innovations in biologics and clinical therapies for active healing. It IPO'd this year and has plans to grow quickly, but will those plans make the company's stock a buy for investors?
Image source: Getty Images.
For further details see:
Will a Powerful Acquisition Make This Early 2021 IPO a Buy?